← Association for Accessible Medicines
FDANonrulemakingFDA-2019-N-1132

The Future of Insulin Biosimilars: Increasing Access and Facilitating the Efficient Development of Biosimilar and Interchangeable Insulin Products; Date for Public Hearing; Request for Comments

RIN
—
Last modified
Jun 25, 2019
Comment window
closed 2615d ago
Association for Accessible Medicines filings
1

Activity

Association for Accessible Medicines filed 1 comment on this docket between Jun 5, 2019 and Jun 5, 2019. 5 other organizations filed here. The comment window closed 2615d ago.

What Association for Accessible Medicines filed (1)

Jun 5, 2019· Comment from Association for Accessible Medicines (AAM)· FDA-2019-N-1132-0326

The Association for Accessible Medicines (AAM), and its Biosimilars Council (Council) (collectively referred to in these comments as AAM), submit these comments to FDAs Part 15 Public Hearing docket The Future of Insulin Biosimilars: Increasing Access and Facilitating the Efficient Development of Biosimilar and Interchangeable Insulin Products. Please find our full comments in attachment.

View on regulations.gov →

Abstract

No abstract recorded.

View on regulations.gov →

Co-filers (5)

See everyone who commented →